- Home
- HPF vs EBS Comparison
HPF vs EBS Comparison
Compare HPF & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPF
- EBS
- Stock Information
- Founded
- HPF 2002
- EBS 1998
- Country
- HPF United States
- EBS United States
- Employees
- HPF N/A
- EBS N/A
- Industry
- HPF Finance Companies
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- HPF Finance
- EBS Health Care
- Exchange
- HPF Nasdaq
- EBS Nasdaq
- Market Cap
- HPF 359.7M
- EBS 423.6M
- IPO Year
- HPF N/A
- EBS 2006
- Fundamental
- Price
- HPF $16.72
- EBS $9.40
- Analyst Decision
- HPF
- EBS Strong Buy
- Analyst Count
- HPF 0
- EBS 2
- Target Price
- HPF N/A
- EBS $13.50
- AVG Volume (30 Days)
- HPF 35.3K
- EBS 805.8K
- Earning Date
- HPF 01-01-0001
- EBS 10-29-2025
- Dividend Yield
- HPF 8.96%
- EBS N/A
- EPS Growth
- HPF N/A
- EBS N/A
- EPS
- HPF N/A
- EBS 2.53
- Revenue
- HPF N/A
- EBS $851,600,000.00
- Revenue This Year
- HPF N/A
- EBS N/A
- Revenue Next Year
- HPF N/A
- EBS $19.24
- P/E Ratio
- HPF N/A
- EBS $3.72
- Revenue Growth
- HPF N/A
- EBS N/A
- 52 Week Low
- HPF $12.99
- EBS $4.02
- 52 Week High
- HPF $16.80
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- HPF 52.06
- EBS 52.52
- Support Level
- HPF $16.60
- EBS $9.13
- Resistance Level
- HPF $16.75
- EBS $10.04
- Average True Range (ATR)
- HPF 0.15
- EBS 0.47
- MACD
- HPF -0.02
- EBS -0.05
- Stochastic Oscillator
- HPF 37.04
- EBS 40.19
About HPF John Hancock Pfd Income Fund II Pfd Income Fund II
John Hancock Preferred Income Fund II is the United States based closed-end, diversified management investment company. Its primary objective is to provide a high level of current income consistent with preservation of capital. The fund's secondary investment objective is to provide growth of capital to the extent consistent with its primary investment objective. The fund's principal investment strategies include to invests a majority of its assets in preferred stocks and other preferred securities, including convertible preferred securities. Its portfolio composition consists of U.S preferred securities, common stocks, foreign preferred securities, corporate bonds, capital preferred securities and short-term investments.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.